Andrew Fisher - Apr 1, 2024 Form 4 Insider Report for Verona Pharma plc (VRNA)

Role
General Counsel
Signature
/s/ Claire Poll, Attorney-in-Fact for Andrew Fisher
Stock symbol
VRNA
Transactions as of
Apr 1, 2024
Transactions value $
$0
Form type
4
Date filed
4/2/2024, 04:15 PM
Previous filing
Mar 7, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRNA Share Options (Right to Buy) Award $0 +2.4M $0.00 2.4M Apr 1, 2024 Ordinary Shares 2.4M $2.01 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
F2 The option vests and becomes exercisable as to 25% on March 4, 2025. The remainder of the shares will vest in 36 equal monthly installments thereafter.